25-LUN-142-AZ (D702FC00001): A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small

Grants and Contracts Details

StatusActive
Effective start/end date6/18/25 → 6/18/27

Funding

  • AstraZeneca Pharmaceuticals LP (domestic): $2.00